Synlogic, Inc. SYBX
Nov 3, 2026, 11:23 AM EST
- YTD
- -10.71%
- 1 year
- -40.83%
- Market cap
- 12.25M
- Revenue (ttm)
- 3.17M
- EPS (ttm)
- -0.06
- Shares out
- 11.70M
- Forward P/E
- -2.94
- YTD return
- -10.71%
- 1-year return
- -40.83%
- Volume
- 1.20K
- Avg volume
- 19.73K
- Open
- 1.00
- Previous close
- 0.98
- Day's range
- 1.00 – 1.00
- 52-week range
- 0.54 – 1.86
- Beta
- 0.84
- Price target
- 1.00 (+0.0%)
2Y -0.4400 (-30.77%)
Key statistics
- Enterprise value
- -3.47M
- PEG ratio
- 0.00
- Price / sales
- 5.10
- Price / book
- 0.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -15.87M
- Total cash
- 19.97M
- Total debt
- 0
- Return on equity
- -158.75%
- Short % of float
- 1.31%
- 50-day average
- 1.42
- 200-day average
- 1.57
Analyst view
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.18 | -0.01 | +0.17 | +94.44% |
| Aug 8, 2024 | Jun 1, 2024 | -0.51 | 0.16 | +0.67 | +131.37% |
| May 14, 2024 | Mar 1, 2024 | -0.80 | -2.60 | -1.80 | -225.00% |
| Mar 19, 2024 | Dec 1, 2023 | -1.11 | -1.71 | -0.60 | -54.05% |
| Nov 9, 2023 | Sep 1, 2023 | -2.55 | -2.57 | -0.02 | -0.78% |
| Aug 10, 2023 | Jun 1, 2023 | -3.90 | -3.15 | +0.75 | +19.23% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 20, 2024 | HC Wainwright & Co. | up | Sell | Neutral |
| Feb 9, 2024 | Chardan Capital | down | Buy | Neutral |
| Feb 9, 2024 | Leerink Partners | down | Outperform | Market Perform |
| Feb 9, 2024 | HC Wainwright & Co. | down | Buy | Sell |
| Dec 11, 2023 | Alliance Global Partners | init | — | Buy |
About Synlogic, Inc.
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- synlogictx.com
News
Reviewing Synlogic (NASDAQ:SYBX) and Oncobiologics (NASDAQ:OTLK) 
Synlogic (NASDAQ:SYBX) Stock Price Crosses Above Fifty Day Moving Average – Here’s What Happened 
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Varex Imaging Corporation (Nasdaq – VREX), Synlogic, Inc. (OTC – SYBX), Bowman Consulting Group Ltd. (Nasdaq – BWMN), Nathan's Famous, Inc. (Nasdaq – NATH) 
SYBX Stock Alert: Halper Sadeh LLC is Investigating Whether Synlogic, Inc. is Obtaining a Fair Price for its Shareholders 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
Crude Oil Gains 2%; D.R. Horton Earnings Top Views 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Dow Falls Over 500 Points; 3M Posts Upbeat Earnings - 12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Friday's After-Market Session
Your note
Sign in to keep a note on SYBX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AWAD ANTOINE | Chief Operating Officer | Sale | Apr 1, 2024 | 33,859 |
| BRENNAN AOIFE M | Chief Executive Officer | Sale | Apr 2, 2023 | 256,301 |
| DOOLEY MARY BETH | Officer | Sale | Oct 28, 2024 | 15,152 |
| JENSEN MICHAEL VANGSTED | Chief Financial Officer | Sale | Apr 2, 2023 | 46,947 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cable Car Capital LLC | 28.32% | 3,312,219 | 4.58M | Sep 29, 2024 |
| NEA Management Company, LLC | 24.99% | 2,922,772 | 4.04M | Sep 29, 2024 |
| Vanguard Group Inc | 1.56% | 183,002 | 252.85K | Sep 29, 2024 |
| FMR, LLC | 1.43% | 166,724 | 230.36K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.61% | 71,928 | 99.38K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.55% | 64,234 | 88.75K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.19% | 139,449 | 192.68K | Sep 29, 2024 |
| Variable Insurance Products Fund-Growth Portfolio | 0.66% | 76,833 | 106.16K | Oct 30, 2024 |
| Fidelity Advisor Equity Growth Fund | 0.37% | 43,116 | 59.57K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.36% | 42,476 | 58.69K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 41,341 | 57.12K | Oct 30, 2024 |
| Fidelity Growth Discovery Fund | 0.25% | 29,260 | 40.43K | Oct 30, 2024 |